Track market-moving stories before they get noisy

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the "Class Period"), of the important November 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Baidu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Baidu class action, go to https://rosenlegal.com/cases/baidu-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Baidu had overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business; (2) as a result, Baidu's revenue was reasonably likely to decline; and (3) as a result of the foregoing, defendants' positive statements about Baidu's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baidu class action, go to https://rosenlegal.com/cases/baidu-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320796

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology

, /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab.

The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays.

"Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."

"Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO," said Brandon Suh, Lunit CEO. "By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why."

This agreement reflects the growing importance of computational pathology in oncology drug development. Routine H&E slides contain rich information about tumor architecture, immune infiltration, stromal organization, and spatial interactions within the tumor microenvironment. However, traditional manual assessment can be difficult to scale and may not fully capture the quantitative and spatial complexity of the tumor-immune interface. AI-powered analysis offers the potential to convert these routinely generated pathology images into reproducible, high-dimensional biomarker data.

The companies expect the work to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning. No clinical outcome data are being announced as part of this release.

*Lunit SCOPE products are for research use only. Not for use in diagnostic procedures or decisions.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit's license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit's license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab's specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab's design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251).

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit's positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company's shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Lunit Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected benefits of the collaboration, the potential use of AI-powered pathology in immuno-oncology development, and the potential application of tumor microenvironment analysis in biomarker research and clinical development. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Neither company undertakes any obligation to update these forward-looking statements, except as required by law.

Summit Forward-Looking Statements

Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about dilution to existing stockholders and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca's ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca's products and other contributions to the clinical trials, the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, the Company's estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a "positive study" as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development-302918571.html

SOURCE Lunit Inc.

Senior creditors to the airline are working with financial adviser PJT Partners and law firm Akin.

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in The Ensign Group, Inc. (NasdaqGS: ENSG) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired publicly traded Ensign securities between February 10, 2022 and June 18, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-ensg/

Ensign investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ensg/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. 

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) Ensign's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (ii) Ensign's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (iii) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (iv) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (v) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (vi) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; and (vii) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model.

The case is Perusek v. The Ensign Group, Inc., No. 26-cv-02963.

WHAT TO DO? If you invested in Ensign and suffered a loss during the relevant time frame, you have until December 7, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Triller Group Inc. (OTC Pink: ILLR) between October 16, 2024 and December 29, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026.

SO WHAT: If you purchased Triller securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Triller's control over and consolidation of Bare Knuckle Fighting Championship ("BKFC") was tenuous, overstated, and/or non-existent; (2) Triller could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements, in part, because of accounting issues related to the foregoing; (3) as a result of all the foregoing, Triller was at an increased risk of being delisted from the NASDAQ; (4) accordingly, Triller's disclosure controls and procedures were deficient, the full scope and severity of issues with its financial controls were understated, and the overall benefits of the Merger were overstated; (5) defendants likewise overstated Triller's ability to address its non-compliance with the NASDAQ's listing requirements; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Triller class action, go to https://rosenlegal.com/cases/triller-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320456

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.

What You May Do

If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."

On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that: (a) sold shares of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) ("D&B") common stock in the open market from May 13, 2025 through August 26, 2025; (b) exchanged shares of D&B common stock into the August 26, 2025 merger of D&B with affiliates of Clearlake Capital Group, L.P. for $9.15 per share in cash (the "Merger"); and/or (c) held shares of D&B common stock as of the May 9, 2025 Record Date for the special meeting of stockholders and whose shares were voted on, or entitled to vote on, the Merger, of the important November 10, 2026 lead plaintiff deadline.

SO WHAT: If you sold Dun & Bradstreet common stock, held shares of D&B common stock on May 9, 2025, or exchanged shares of D&B common stock as a result of its merger, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Dun & Bradstreet class action, go to https://rosenlegal.com/cases/dun-bradstreet-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The lawsuit seeks to recover damages on behalf of investors that were damaged as a result of allegedly false and misleading statements and omissions of material facts in D&B's March 23, 2025 announcement of the Merger and the May 13, 2025 definitive proxy statement on Schedule 14A (the "Proxy"). Among other things, the complaint alleges the Proxy and other solicitation materials misled investors regarding the true value of D&B and the subject transaction, including portraying the Merger as the product of an ordinary-course strategic review and organic arm's-length interest in D&B, while omitting Executive Chairman Foley's personal interest in a quick sale. The complaint also alleges the Proxy omitted Bank of America Securities' valuations of superior alternatives to a whole-company sale, misstated that D&B's Board of Directors had approved downward revisions to D&B's financial projections and failed to disclose long-standing, material ties between Foley and D&B's financial and legal advisors.

To join the Dun & Bradstreet class action, go to https://rosenlegal.com/cases/dun-bradstreet-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320800

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fluence Energy, Inc. (NASDAQ: FLNC) between November 24, 2025 and September 16, 2026, inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Fluence Energy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fluence Energy class action, go to https://rosenlegal.com/cases/fluence-energy-inc-2026-09/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Fluence Energy’s ability to deliver its backlog and recognize the revenue underlying its fiscal 2026 guidance depended on new contract manufacturing facilities, including facilities that were not completed, not operational, and/or not capable of producing at the volumes the guidance assumed; (2) the corrective measures Fluence Energy had implemented to address production problems at its contract manufacturers were not remediating those problems, which persisted and extended to Fluence Energy’s new facilities; (3) as a result, a material portion of the backlog that defendants represented as “securing” or “covering” Fluence Energy’s fiscal 2026 revenue guidance were likely to be delivered and recognized in fiscal 2026; and (4) as a result of the foregoing, defendants’ positive statements about Fluence Energy’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fluence Energy class action, go to https://rosenlegal.com/cases/fluence-energy-inc-2026-09/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Pennsylvania.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-duol/

Duolingo investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-duol/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. 

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) Duolingo was deliberately adding friction to the user experience, through sharply increased ad volume, upselling of subscription tiers, and declining product quality, which Defendants knew would drive users away from the app and ultimately slow Daily Active User ("DAU") growth; (ii) Duolingo's extensive A/B testing showed Defendants that added friction in the free user experience was hurting DAU growth; (iii) Duolingo's rapidly produced AI content was degrading its product offerings, harming the user experience and user trends, and putting the sustainability of Duolingo's financial performance at risk; and (iv) rather than fueling sustained growth and strong user momentum through content and "product improvements" that "get improved retention," Duolingo's monetization push and lower-quality AI content were, as its ongoing A/B testing revealed, eroding both the product experience and the value of its subscription tiers.

The case is City of Dearborn Heights Act 345 Police & Fire Retirement System v. Duolingo, Inc., No. 26-cv-02199.

WHAT TO DO? If you invested in Duolingo and suffered a loss during the relevant time frame, you have until December 7, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Papa John's International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Papa Johns common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Papa Johns' transformation; notably, that it was "taking longer than expected," and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate Papa Johns' declining competitive position. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320628

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that CooperCompanies may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased CooperCompanies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-cooper-companies-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On September 10, 2026, The Motley Fool published an article entitled "Why is Cooper Companies Stock Down 15% Today?". The article stated that Cooper Companies stock fell "after the company's earnings report disappointed Wall Street with weak guidance and a decision to not sell Cooper Surgical."

On this news, Cooper Companies' stock fell 14.6% on September 10, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320785

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026, both dates inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AST SpaceMobile, Inc. (NASDAQ: ASTS) between March 4, 2025 and July 15, 2026, inclusive (the "Class Period"), of the important November 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased AST SpaceMobile securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AST SpaceMobile class action, go to https://rosenlegal.com/cases/ast-spacemobile-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AST SpaceMobile's increasing capital requirements were likely to increase AST SpaceMobile's debt load and share dilution with greater frequency and at greater scale than defendants had signaled to investors; (2) accordingly, defendants had overstated the sufficiency of AST SpaceMobile's capital and liquidity position to achieve AST SpaceMobile's strategic and business goals; (3) defendants likewise overstated the durability of AST SpaceMobile's competitive position in the satellite D2C market; (4) even following the EchoStar Transaction, defendants continued overstating AST SpaceMobile's competitive position in the satellite D2C market; (5) AST SpaceMobile was experiencing slow user adoption in the U.S. and Japan; (6) the foregoing was likely to have a significant negative impact on AST SpaceMobile's business and financial prospects; and (7) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AST SpaceMobile class action, go to https://rosenlegal.com/cases/ast-spacemobile-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320793

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of D-Wave Quantum Inc. (NASDAQ: QBTS) between February 26, 2026 and August 25, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2026.

SO WHAT: If you purchased D-Wave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the D-Wave class action, go to https://rosenlegal.com/cases/dwave-quantum-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) D-Wave's Bookings had declined in 2025; (2) D-Wave's purported record 2026 Bookings did not reflect new or expanding commercial adoption, because they consisted predominantly of two contracts signed before the Class Period and, upon information and belief, no comparable new contracts were being secured; (3) upon information and belief, D-Wave was not on track to convert its system-sales pipeline into new Bookings; (4) upon information and belief, the delivery of D-Wave's systems, and the associated revenue, was slipping to the fourth quarter of 2026 and into 2027; and (5) as a result, defendants' positive statements about D-Wave's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the D-Wave class action, go to https://rosenlegal.com/cases/dwave-quantum-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320794

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Build-A-Bear Workshop, Inc. (NYSE: BBW) resulting from allegations that Build-A-Bear may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Build-A-Bear securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/buildabear-workshop-inc-bbw/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: Rosen Law Firm is investigating potential civil securities claims.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320781

Source: The Rosen Law Firm PA

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alphabet Inc. (NASDAQ: GOOGL, GOOG) between May 19, 2026 and July 16, 2026, inclusive (the "Class Period"), of the important December 1, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Alphabet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Alphabet Inc. class action, go to https://rosenlegal.com/cases/alphabet-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the Gemini 3.5 Pro was delivering disappointing training results; (2) as a result, the launch of Gemini 3.5 Pro would be significantly delayed; and (3) as a result of the foregoing, defendants' positive statements about Alphabet's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Alphabet Inc. class action, go to https://rosenlegal.com/cases/alphabet-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320778

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Shares of AT&T (T -7.96%) fell 8% on Friday after a new report stoked investors' fears of a potentially disruptive encroachment by Space Exploration Technologies (SPCX +1.89%) into the lucrative U.S. wireless market.

Image source: Getty Images.

A worrisome new threatSpaceX is in talks to obtain access to at least 80,000 cell sites across the U.S., according to a report by Bloomberg. The telecommunications infrastructure would serve a crucial role in SpaceX CEO Elon Musk's plan to create a formidable rival to AT&T, Verizon, and T-Mobile.

During SpaceX's third-quarter earnings call on Oct. 20, chief operating officer Gwynne Shotwell said Starlink Mobile's monthly users jumped 37% to over 22 million. The satellite-to-cellular network connects ordinary smartphones to SpaceX's low-Earth orbit constellation.

$20.93-$1.81 (-7.96%)

NYSE · As of 4:00 PM ET 10/23/26

The space technology titan recently acquired a nationwide portfolio of low-band spectrum licenses that it says "will pave the way for Starlink Mobile to become a major mobile carrier in the U.S."

"We will be building out our terrestrial network such that there is broad-based connectivity anywhere that SpaceX and Starlink are allowed to operate," Musk said.

AT&T won't go down without a fightSpaceX isn't an adversary to be taken lightly. However, building another nationwide wireless carrier won't be cheap, with costs likely to reach tens of billions of dollars. It's also likely to take time -- and perhaps longer than today's sell-off in AT&T's share price would suggest.

In the meantime, AT&T continues to win new customers. The telecom leader added 379,000 postpaid phone subscribers in the third quarter, along with 442,000 fiber and 327,000 fixed wireless customers.

AT&T's revenue, in turn, rose 5% to $32.3 billion, and management lifted its full-year adjusted earnings guidance to $2.40 per share. Following today's declines, AT&T's stock can be had for less than 9 times its projected 2026 profits.

Moreover, the wireless leader expects its cash profits to grow -- not fall -- in the coming years. AT&T sees its free cash flow rising to over $21 billion in 2028, up from $18 billion this year.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends T-Mobile US and Verizon Communications. The Motley Fool has a disclosure policy.

Autodesk (ADSK - Free Report) closed the most recent trading day at $252.20, moving -1.08% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

The stock of design software company has risen by 20.63% in the past month, leading the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.

Market participants will be closely following the financial results of Autodesk in its upcoming release. On that day, Autodesk is projected to report earnings of $3.07 per share, which would represent year-over-year growth of 14.98%. At the same time, our most recent consensus estimate is projecting a revenue of $2.13 billion, reflecting a 14.96% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $12.62 per share and a revenue of $8.32 billion, signifying shifts of +21% and +15.48%, respectively, from the last year.

Any recent changes to analyst estimates for Autodesk should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. As of now, Autodesk holds a Zacks Rank of #3 (Hold).

In terms of valuation, Autodesk is presently being traded at a Forward P/E ratio of 20.2. This signifies a discount in comparison to the average Forward P/E of 20.75 for its industry.

We can additionally observe that ADSK currently boasts a PEG ratio of 1.3. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Internet - Software was holding an average PEG ratio of 1.31 at yesterday's closing price.

The Internet - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 83, finds itself in the top 34% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

For the quarter ended September 2026, Halliburton (HAL - Free Report) reported revenue of $5.7 billion, up 1.8% over the same period last year. EPS came in at $0.60, compared to $0.58 in the year-ago quarter.

The reported revenue represents a surprise of +1.98% over the Zacks Consensus Estimate of $5.59 billion. With the consensus EPS estimate being $0.58, the EPS surprise was +3.45%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halliburton performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Latin America: $1.12 billion versus $1.06 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.Revenue- Europe/Africa/CIS: $1.02 billion versus the three-analyst average estimate of $924.3 million. The reported number represents a year-over-year change of +22.7%.Revenue- North America: $2.16 billion versus the three-analyst average estimate of $2.29 billion. The reported number represents a year-over-year change of -8.6%.Revenue- Middle East/Asia: $1.41 billion versus $1.3 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.Revenue- Drilling and Evaluation: $2.61 billion compared to the $2.41 billion average estimate based on five analysts. The reported number represents a change of +10% year over year.Revenue- Completion and Production: $3.09 billion compared to the $3.16 billion average estimate based on five analysts. The reported number represents a change of -4.2% year over year.Operating income- Completion and Production: $457 million versus the five-analyst average estimate of $515.8 million.Operating income- Drilling and Evaluation: $391 million compared to the $338.22 million average estimate based on five analysts.Operating income- Corporate and other: $-75 million versus $-102.5 million estimated by two analysts on average.View all Key Company Metrics for Halliburton here>>>

Shares of Halliburton have returned +1.3% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Western Digital (WDC -2.97%) gave investors almost everything they could've asked for on Thursday. The hard drive maker's revenue in its fiscal first quarter of 2027 (the period ending Oct. 2, 2026) jumped 55% year over year to $4.38 billion. The company also boosted its dividend 17%, and its non-GAAP (adjusted) earnings per share climbed 161%. The revenue number beat the $4.0 billion to $4.2 billion range management had guided for in August.

But shares haven't seen much of a lift. At roughly $353 as of this writing, the stock is worth less than half what it was at its June 18 record close of about $746 -- a drop of about 53%.

Has the stock fallen far enough to make it a buy? I think the answer has less to do with the quarter itself and more to do with how long hard drive prices can keep rising.

Image source: The Motley Fool.

Pricing is still speeding upShowing how tight the market for data storage remains, Western Digital's average price per terabyte rose 28% year over year in fiscal Q1, up from growth in the high teens in the previous quarter. Exabytes shipped (a measure of all the storage capacity sold) rose 22%, and management expects this growth to pick up as new, higher-capacity drives ramp up over the next year or so.

More storage sold at higher prices is why revenue growth keeps accelerating, from 44% in the prior quarter to 55% in fiscal Q1.

Management's guidance for the fiscal second quarter calls for even faster growth of 66% to 72%, or around $5.1 billion in revenue at the midpoint. Margins are widening, too. Adjusted gross margin rose to 58.1% in fiscal Q1, up from 54.4% in the prior quarter and 43.9% a year ago, and management expects 60% to 61% in fiscal Q2.

Also, free cash flow more than doubled year over year to $1.38 billion, and much of it went back to shareholders. Western Digital repurchased around $1 billion of its stock in the quarter and boosted its quarterly dividend to $0.175 a share.

Why have shares fallen so far?The slide seems to reflect worry over where hard drive pricing heads next, not the current results. Prices of any storage product can swing sharply when supply catches up to demand.

Shares fell around 10% on Oct. 2 after a report that Toshiba plans to double its capacity to build hard drives for artificial intelligence data centers.

Additionally, when Western Digital reported its fiscal fourth quarter in August, the stock slid around 13% the next day despite 44% revenue growth.

Management pushed back on Thursday's earnings call. CEO Irving Tan said the company has good demand visibility through 2030 and 2031 for its top seven customers. CFO Kris Sennesael said there's "definitely further room" for price-per-terabyte growth in the next three to four quarters. But he also noted that the growth in price per terabyte would probably slow a bit eventually, and that the further out you look, the less of Western Digital's business is covered by pricing terms in its long-term agreements.

Put simply, the company can see demand for years ahead. It can't see the price it'll get for that demand nearly as far out.

Earnings are outrunning the stockThat uncertainty helps explain why the valuation looks so modest. Shares cost around 27 times adjusted earnings over the past four quarters. But annualize the $5.80 midpoint of management's fiscal second-quarter adjusted earnings-per-share guidance, and the price-to-earnings ratio drops to around 15.

$343.67-$10.52 (-2.97%)

NASDAQ · As of 4:00 PM ET 10/23/26

For a company whose adjusted earnings per share more than doubled last quarter, a price-to-earnings multiple of 15 is low. Investors seem to expect today's profits to fade.

Of course, some fade is reasonable to expect. Price per terabyte likely won't keep rising 28% a year forever, and more supply from a rival is one way a pricing boom might end.

In early September, I favored Seagate Technology over Western Digital, mostly because Western Digital hadn't shown how much of its demand past this year was locked in. Thursday's call answered some of that, on demand if not on price. And the stock's more than $100 lower than it was then.

So, is Western Digital stock a buy after its latest report? At around 15 times annualized guided earnings, I think much of the risk of a pricing slowdown is already built into the share price. I'd consider opening a small position here, and I'd want to see price per terabyte keep rising into 2027 before buying more.

The main risk is that hard drive pricing turns earlier than management expects.

In the latest trading session, Cenovus Energy (CVE - Free Report) closed at $32.88, marking a +2.72% move from the previous day. This change outpaced the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Heading into today, shares of the oil company had gained 2.33% over the past month, lagging the Oils-Energy sector's gain of 5.63% and outpacing the S&P 500's loss of 1.21%.

The investment community will be closely monitoring the performance of Cenovus Energy in its forthcoming earnings report. The company is forecasted to report an EPS of $1.21, showcasing a 132.69% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $11.71 billion, showing a 22.2% escalation compared to the year-ago quarter.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.12 per share and revenue of $44.01 billion. These totals would mark changes of +167.53% and +23.79%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Cenovus Energy. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 15.51% higher. As of now, Cenovus Energy holds a Zacks Rank of #1 (Strong Buy).

With respect to valuation, Cenovus Energy is currently being traded at a Forward P/E ratio of 7.77. This signifies a discount in comparison to the average Forward P/E of 10.37 for its industry.

The Oil and Gas - Integrated - Canadian industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 3, positioning it in the top 2% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

In the latest close session, Dick's Sporting Goods (DKS - Free Report) was down 2.76% at $144.67. This move lagged the S&P 500's daily loss of 0.52%. Meanwhile, the Dow lost 1.24%, and the Nasdaq, a tech-heavy index, lost 0.21%.

Prior to today's trading, shares of the sporting goods retailer had gained 11.65% outpaced the Retail-Wholesale sector's gain of 2.31% and the S&P 500's loss of 1.21%.

Market participants will be closely following the financial results of Dick's Sporting Goods in its upcoming release. The company is expected to report EPS of $1.39, down 32.85% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $5.06 billion, indicating a 21.51% growth compared to the corresponding quarter of the prior year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $11.69 per share and revenue of $22.05 billion, indicating changes of -11.44% and +28.08%, respectively, compared to the previous year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Dick's Sporting Goods. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.12% lower within the past month. Dick's Sporting Goods is currently a Zacks Rank #5 (Strong Sell).

From a valuation perspective, Dick's Sporting Goods is currently exchanging hands at a Forward P/E ratio of 12.73. This represents a discount compared to its industry average Forward P/E of 16.15.

Also, we should mention that DKS has a PEG ratio of 2.82. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DKS's industry had an average PEG ratio of 1.9 as of yesterday's close.

The Retail - Miscellaneous industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 43, putting it in the top 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DICK’S Sporting Goods, Inc. (NYSE: DKS) between September 8, 2025 and August 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline.

SO WHAT: If you purchased DICK’S Sporting Goods common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DICK’S Sporting Goods class action, go to https://rosenlegal.com/cases/dicks-sporting-goods/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Dick’s cleanup efforts concerning Foot Locker’s inventory were not complete, and, in fact, Foot Locker remained saddled with unproductive and stagnant legacy footwear; (2) Foot Locker heavily relied on legacy footwear products that were particularly vulnerable to intensifying promotional pressures across the athletic footwear industry; (3) in turn, Dick’s was significantly exposed to an industry-wide environment of excess inventory and resulting promotional activity; (4) accordingly, Dick’s was unable to achieve the sales growth, margins, and profits it touted to investors; and (5) as a result of the above, defendants’ positive statements about Dick’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DICK’S Sporting Goods class action, go to https://rosenlegal.com/cases/dicks-sporting-goods/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

In the latest trading session, Paccar (PCAR - Free Report) closed at $107.26, marking a -2.13% move from the previous day. This change lagged the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Coming into today, shares of the truck maker had lost 0.98% in the past month. In that same time, the Auto-Tires-Trucks sector lost 1.99%, while the S&P 500 lost 1.21%.

The investment community will be paying close attention to the earnings performance of Paccar in its upcoming release. The company is slated to reveal its earnings on October 27, 2026. The company is predicted to post an EPS of $1.61, indicating a 43.75% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $7.56 billion, up 23.87% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $5.91 per share and a revenue of $28.62 billion, demonstrating changes of +17.96% and +9.08%, respectively, from the preceding year.

Investors should also note any recent changes to analyst estimates for Paccar. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Paccar possesses a Zacks Rank of #3 (Hold).

Investors should also note Paccar's current valuation metrics, including its Forward P/E ratio of 18.56. This represents a premium compared to its industry average Forward P/E of 16.3.

It's also important to note that PCAR currently trades at a PEG ratio of 1.26. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Automotive - Domestic industry currently had an average PEG ratio of 1.26 as of yesterday's close.

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 211, positioning it in the bottom 15% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

VICI Properties Inc. (VICI - Free Report) ended the recent trading session at $23.76, demonstrating a -1.08% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Heading into today, shares of the company had gained 3.22% over the past month, outpacing the Finance sector's loss of 0.78% and the S&P 500's loss of 1.21%.

Investors will be eagerly watching for the performance of VICI Properties Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 28, 2026. It is anticipated that the company will report an EPS of $0.62, marking a 3.33% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $1.06 billion, up 5.67% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $2.47 per share and a revenue of $4.22 billion, demonstrating changes of +3.78% and +5.26%, respectively, from the preceding year.

Investors should also note any recent changes to analyst estimates for VICI Properties Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. VICI Properties Inc. is currently sporting a Zacks Rank of #2 (Buy).

Looking at valuation, VICI Properties Inc. is presently trading at a Forward P/E ratio of 9.73. For comparison, its industry has an average Forward P/E of 11.85, which means VICI Properties Inc. is trading at a discount to the group.

The REIT and Equity Trust - Other industry is part of the Finance sector. With its current Zacks Industry Rank of 95, this industry ranks in the top 39% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.